What the WHO Pandemic Agreement Actually Asks of Countries

When COVID-19 hit, richer countries locked up most of the early vaccine supply while poorer nations waited months, sometimes years, for their first doses. That gap is the reason the World Health Organization spent years negotiating a new pandemic agreement, finally adopted by its member states in 2025. It’s worth understanding what this deal actually does, because the popular version—that it hands WHO power to declare lockdowns or override national governments—isn’t accurate.

Why This Treaty Exists

The pandemic agreement grew directly out of frustration with how COVID-19 played out. Wealthy countries had pre-purchased most vaccine doses before poorer countries could access any. Genetic data on new variants sometimes moved slower than it should have, because countries worried that sharing it wouldn’t benefit them directly. The goal of the new agreement is to fix those specific failures before the next outbreak, not to create a global health government.

The Core Trade: Data for Vaccines

The heart of the agreement is a system called Pathogen Access and Benefit Sharing, or PABS. It works like a deal: countries agree to quickly share samples of dangerous pathogens and their genetic sequences with WHO and researchers. In return, manufacturers who use that shared data to build vaccines, treatments, or diagnostic tests agree to set aside a portion of what they produce—in real time, as it’s made—for WHO to distribute to countries that can’t afford to bid at the front of the line.

This matters because genetic sequence data is often what allows scientists to design a vaccine within weeks of a new pathogen emerging. Countries where outbreaks first appear have sometimes hesitated to share that data quickly, worried they’d get nothing back once companies elsewhere profited from it. The agreement tries to remove that hesitation by guaranteeing a share of the payoff up front.

What Countries Are Actually Required to Do

Stripped of the political noise, the obligations fall into a few categories:

• Share pathogen information promptly during a declared public health emergency, rather than sitting on data for competitive or political reasons.
• Strengthen domestic health systems, including surveillance networks that can spot new outbreaks early and lab capacity to analyze them.
• Support technology transfer, meaning wealthier countries and manufacturers are encouraged to help other regions build their own capacity to produce vaccines and treatments, rather than relying entirely on a handful of manufacturing hubs.
• Coordinate on supply chains so that raw materials and manufacturing capacity aren’t hoarded during a crisis, which was a real problem in 2020 and 2021.

Notably absent: any requirement to adopt specific lockdown measures, mask mandates, travel restrictions, or vaccine mandates. Those decisions remain entirely up to individual governments. The agreement is explicit that it does not give WHO authority to direct national health policy. That distinction has gotten lost in a lot of the public debate, but it’s central to what negotiators actually agreed to.

Why the Sovereignty Fear Is Overstated

Much of the resistance to the agreement, both from certain governments and from segments of the public, centered on a fear that WHO would gain power to override national decisions during a health emergency. The final text doesn’t do that. WHO can recommend actions and coordinate information, much as it already does, but it has no enforcement mechanism to compel any country to act. Compliance is essentially voluntary, backed mainly by the incentive of participating in the benefit-sharing system.

That voluntary structure is also the agreement’s biggest weakness. Without real penalties for countries that ignore their commitments, the deal relies heavily on goodwill and the practical benefit of staying inside the system. If a future outbreak puts pressure on that goodwill, it’s an open question how well the commitments hold up.

Not Everyone Is On Board

The agreement doesn’t have universal buy-in. Some countries have stayed on the sidelines or withdrawn from broader WHO participation altogether, which limits how effective a truly global response can be. An agreement only works as well as the number of major countries actually inside it, particularly ones with significant vaccine manufacturing capacity. Getting enough countries to formally ratify the agreement, rather than just adopt it in principle, is the next major hurdle, and that process typically takes years.

What This Means for You

For most people, the practical effect won’t be visible until the next serious outbreak. If it works as designed, that’s the whole point: a pandemic agreement is meant to be background infrastructure, not something you notice day to day. The real test will come the next time a novel pathogen emerges somewhere in the world. Will affected countries share data quickly? Will manufacturers actually set aside the promised share of vaccines for lower-income countries, or will political pressure at home override that commitment once again?

The agreement is a genuine attempt to close the gap that made COVID-19 so unequal in its impact. Whether it succeeds depends less on the text itself and more on whether countries follow through when the pressure is real. That’s usually where good intentions in international agreements either prove their worth or quietly fall apart.